~~<i id='6AD06789F9'><strike id='6AD06789F9'><tt id='6AD06789F9'><pre id='6AD06789F9'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

comprehensive

author：knowledge 2025-09-27 16:48:24 - browse：59471

WASHINGTON — Back in 1980, when the Food and Drug Administration approved the use of lead acetate in hair dyes, little was known about the way skin absorbs toxic chemicals.

The skin — and the scalp in particular — were considered tough barriers to break, and many public health officials believed that even if small amounts of lead got through, or were inhaled, it couldn’t really hurt anyone.

But in science, 37 years is an eon. So a coalition of environmental groups, academics, and consumer advocates is pushing FDA to take lead acetate off the market. It is now permitted as a color additive.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： New company forms to vet health AI models, root out weaknesses

entertainment

hotspot

knowledge

hotspot

entertainment

LONDON--Thetechnicolor,dance-filledLondonPridemarchbrieflycametoahaltSaturdayasclimateactivistsblock

WSS

New documents shed light on MD Anderson Cancer Institute feud

Antivenom research: Lessons from HIV applied in search for universal antidote

'Cuddling' is just what the doctor ordered for a 200

Prosecutors seek bail revocation for FTX founder Sam Bankman

Calls for Trump's election interference trial to be televised part of long debate

STAT readers on older presidents, polypills, Medicare, and more

entertainment

comprehensive

entertainment

Heart attack and stroke risk calculators need revising

Parkland mass shooting to be reenacted for lawsuit

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

R1 RCM gets $5.8 billion buyout offer from private equity firm

Moonlake's readout produced a cash windfall. Risks remain

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

After affirmative action ruling, medical educators look to 'holistic review'

Climate activists disrupt London Pride march to protest corporate sponsorship

hotspot

Lifetime voting ban for felony convictions struck down in Mississippi

Jailed Russian opposition leader Alexey Navalny gets 19 more years in prison

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Medical mystery: When an infection after surgery isn’t what it seems

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

hotspot

knowledge

hotspot

entertainment